出 处:《中国实用医药》2025年第2期12-15,共4页China Practical Medicine
基 金:第七批全国名老中医药专家学术经验继承项目(项目编号:国中医药人教函[2022]76号);第五批全国中医优秀临床人才研修项目(项目编号:国中医药人教函[2022]1号);广东省中医药局重点资助项目(项目编号:20241327);惠州市科技研发计划重点项目(项目编号:2022CZ010425)。
摘 要:目的探究培土生金法联合金水相生法治疗慢性阻塞性肺疾病(COPD)稳定期肺肾气阴两虚证患者的临床疗效。方法将72例COPD稳定期肺肾气阴两虚证患者随机分为治疗组与对照组,各36例。在8周观察期间,对照组脱落6例,治疗组脱落5例,实际对照组纳入30例有效病例,治疗组纳入31例有效病例。对照组给予培土生金法(玉屏风颗粒)联合西医基础治疗,治疗组给予培土生金法联合金水相生法(补肺平喘膏)及西医基础治疗。比较两组临床疗效、肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)]、6 min步行距离(6MWD)、改良版英国医学研究委员会呼吸困难问卷(mMRC)评分、安全性。结果治疗后,治疗组患者的总有效率90.3%明显高于对照组的60.0%(P<0.05)。治疗后,治疗组FVC(2.32±0.74)L较治疗前的(2.17±0.65)L提高(P<0.05),治疗组及对照组FEV1[(1.42±0.36)、(1.39±0.41)L]均较治疗前[(1.22±0.33)、(1.23±0.40)L]提高(P<0.05)。治疗后,两组患者的6MWD均较治疗前延长,且治疗组患者的6MWD(398.39±24.61)m比对照组的(386.77±16.81)m长(P<0.05)。治疗后,两组患者的mMRC评分均较治疗前降低,且治疗组的mMRC评分较对照组低(P<0.05)。两组患者治疗后均无不良反应,治疗后安全性指标均无明显异常。结论对于COPD稳定期肺肾气阴两虚证患者,培土生金法联合金水相生法可有效改善患者的肺功能,且相较于培土生金法,其在提高治疗效果、缓解临床症状、改善肺功能、提高运动耐量方面更有优势,并具有良好的安全性。Objective To explore the clinical efficacy of the method of reinforcing the earth to generate the metal in combination with the method of mutual promotion between lung and kidney for the treatment of stable chronic obstructive pulmonary disease(COPD)with Qi and Yin deficiency of lung and kidney syndrome.Methods A total of 72 patients with Qi and Yin deficiency of lung and kidney syndrome in the stable stage of COPD were randomly into the treatment group and the control group,each with 36 cases.During the 8-week observation period,there were 6 drop-out cases in the control group and 5 drop-out cases in the treatment group.30 effective cases were included in the actual control group and 31 effective cases were included in the treatment group.The control group was given the method of reinforcing the earth to generate the metal(Yupingfeng Granules)and Western basic treatment,while the treatment group was given the method of reinforcing the earth to generate the metal in combination with the method of mutual promotion between lung and kidney(Bufei Pingchuan ointment)and Western medicine therapy.Both groups were compared in terms of clinical efficacy,pulmonary function indicators[forced vital capacity(FVC),forced expiratory volume in one second(FEV1)],6-min walking distance(6MWD),modified Medical Research Council(mMRC)score,and safety.Results After treatment,the total effective rate of 90.3% in the treatment group was significantly higher than 60.0%in the control group(P<0.05).After treatment,FVC(2.32±0.74)L in the treatment group was higher than(2.17±0.65)L before treatment(P<0.05).FEV1[(1.42±0.36),(1.39±0.41)L]in the treatment group and the control group were higher than those before treatment[(1.22±0.33),(1.23±0.40)L](P<0.05).After treatment,6MWD in both groups was longer than that before treatment;6MWD(398.39±24.61)m in the treatment group was longer than(386.77±16.81)m in the control group(P<0.05).After treatment,the mMRC score in both groups was lower than that before treatment,and the mMRC score of the t
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...